

Breakthroughs that change patients' live



Direct Healthcare Professional Communication

08-Dec-2025

Tranexamic Acid Intravenous Formulations – Serious Including Fatal Adverse Reactions Due to Inadvertent Intrathecal Administration

Dear Healthcare professional,

Pfizer in agreement with the Saudi Food and Drug Authority (SFDA) would like to inform you of the following:

Summary

- **Tranexamic acid injectable formulation is authorised for intravenous use only. Intrathecal, epidural, intraventricular and intracerebral use of Tranexamic Acid injectable is contraindicated.¹**
- **Extreme caution should be taken when storing, handling and administering intravenous formulations of Tranexamic Acid to ensure the correct route of administration. This includes clearly labelling syringes containing Tranexamic Acid for intravenous use only and storing Tranexamic Acid injectables separately from injectable local anaesthetics.²**
- **Serious, including fatal, adverse reactions have been reported after inadvertent intrathecal administration due to mix-ups, mostly with injectable local anaesthetics.²**

Background on the safety concern

Tranexamic Acid is an antifibrinolytic indicated in adults and children from one year of age in prevention and treatment of haemorrhages due to general or local fibrinolysis. Specific indications include Haemorrhage caused by general or local fibrinolysis (such as menorrhagia and metrorrhagia, gastrointestinal bleeding, haemorrhagic urinary disorders further to prostate surgery or surgical procedures affecting the urinary tract), Ear Nose Throat surgery (adenoidectomy, tonsillectomy, dental extractions), Gynaecological surgery or disorders of obstetric origin, Thoracic and abdominal surgery and other major surgical intervention such as cardiovascular surgery, Management of haemorrhage due to the administration of a fibrinolytic agent.¹

Tranexamic Acid injectable is authorised for intravenous use only. It **must not** be administered intrathecally, epidurally, by intraventricular injection or by intracerebral application.¹ Cases of medication errors have been identified, including cases reported in the EU, where Tranexamic Acid injection was inadvertently administered intrathecally or epidurally.² Most of these cases involved mix-ups of vials or ampoules resulting in erroneous administration of Tranexamic Acid instead of the intended injectable local anaesthetic (e.g. bupivacaine, levobupivacaine, prilocaine).²

When administered intrathecally, serious patient harms were reported including prolonged hospitalisation and death. Serious adverse reactions following inadvertent intrathecal administration included severe back, gluteal and lower limb pain, myoclonus and generalised seizures and cardiac arrhythmias.²

Healthcare professionals should take extreme care to ensure correct route of administration of Tranexamic Acid.² Healthcare professionals should be aware of the potential for a mix-up between Tranexamic Acid and other injectable products which could result in inadvertent administration of Tranexamic Acid by an incorrect route.² In particular, this includes intrathecally administered injectable products that may be used during the same procedure as Tranexamic Acid.² In order to reduce the risk of fatal medication errors due to incorrect route of administration, syringes containing Tranexamic Acid should be clearly labelled for identification and correct route of administration.²

It is also advised to store Tranexamic Acid injectables separately from injectable local anaesthetics to prevent accidental mix-up.²

The product information of injectable Tranexamic Acid products, including the outer packaging, will be updated to strengthen the warnings that Tranexamic Acid injection should only be administered intravenously.

Call for reporting

Healthcare professionals should report any suspected adverse reactions or medication errors associated with the use of Tranexamic Acid to:

-The National Pharmacovigilance Centre (NPC) at Saudi Food and Drug Authority (SFDA):

SFDA Call Center: 19999

E-mail: npc.drug@sfdagov.sa

Website:



Pharmacovigilance Department in the company:

Telephone: +966 12 2293633

E-mail: SAU.AEReporting@pfizer.com

Company contact point

For more information, please contact Pfizer Medical Information: MedInfoMEandAfrica@pfizer.com

This document is approved by The Executive Directorate of Pharmacovigilance, at SFDA.

Sincerely,
Salha I. Almomen, MD
Medical Director, Pfizer Saudi

References:

- 1- Cyklokapron(Traneximic acid), summary of product characteristics, Saudi Arabia, February 2025
- 2- PRAC PSUR assessment report March 2nd, 2025

" في حال وجود ملاحظات على المواد المقدمة يرجى التواصل مع الهيئة العامة للغذاء و الدواء على الرقم الموحد 19999 "

For reporting adverse Events: SAU.AEReporting@Pfizer.com

Please do not reply to this email as this is an unmonitored inbox.

For Healthcare Professionals Only

[Click here to Unsubscribe](#)

This information is intended only for healthcare professionals in Saudi Arabia. The product information provided in this site is intended only for healthcare professionals in Saudi Arabia. The products discussed herein may have different product labelling in different countries. Pfizer Inc. does not suggest or recommend the use of Pfizer products in any manner other than as described in the prescribing information approved by Saudi Food and Drug Administration (SFDA). Pfizer Scientific Technical Limited company is a subsidiary of Pfizer Inc., a pharmaceutical company committed to helping people improve their health by discovering and developing medicines.

© 2026 Pfizer Inc. All rights reserved.



Pfizer Scientific Technical Limited company,
Al Riyadh – Al Aqeeq Dis, King Abdullah Financial District, Building 4.07 Postal Code 13519,
Tel: +966 12 2293500, Fax: +966 12 2293692